Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment
Abstract Aim The aim of this study was to explore the accuracy of the diagnosis of gastro-esophageal reflux disease (GERD) through tegoprazan treatment trials, and to analyze factors that may influence test accuracy. Methods This was a single-blind, single-arm 2 weeks tegoprazan treatment trials fro...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | BMC Gastroenterology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12876-025-03981-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849763622313525248 |
|---|---|
| author | Peiwen Dong Lin Lin Kaidi Sun Feng Tang Qian Li Xinxu Zhou Fuli Liu Zhilin Yang Jiao Li Lin Jiang Ping Zhao Xiaobin Sun Qiong Wang |
| author_facet | Peiwen Dong Lin Lin Kaidi Sun Feng Tang Qian Li Xinxu Zhou Fuli Liu Zhilin Yang Jiao Li Lin Jiang Ping Zhao Xiaobin Sun Qiong Wang |
| author_sort | Peiwen Dong |
| collection | DOAJ |
| description | Abstract Aim The aim of this study was to explore the accuracy of the diagnosis of gastro-esophageal reflux disease (GERD) through tegoprazan treatment trials, and to analyze factors that may influence test accuracy. Methods This was a single-blind, single-arm 2 weeks tegoprazan treatment trials from March 2023 to April 2024. Patients with ‘typical’ reflux or heartburn as their most troublesome symptom who were considered likely to have GERD were recruited.: Patients were submitted to endoscopy and/or esophageal pH monitoring. After the recording patient used tegoprazan for 2 weeks. This was defined as positive for tegoprazan therapy if the scores for symptoms have decreased to 50%, 75% and 100% of the baseline after 1 and 2 weeks. Calculate different sensitivity, specificity and Youden index for each criterion. Results This represents a mid-term report from the study, with 98 and 91 fully evaluable at one and two weeks. The Youden index indicated that a symptom relief of > 75% after one week offers greater diagnostic value with sensitivity and specificity of 77.5% and 51.9%. Multivariate regression analysis indicated that lower BMI, preference for coffee, endoscopic mucosal erosion, ineffective esophageal peristalsis and positive SAP are independent risk factors predicting the efficacy of P-CAB treatment. Conclusions The P-CAB test (tegoprazan) presents a promising tool for the diagnosis of GERD. A one-week treatment with a criterion of 75% reduction in symptom scores from baseline may be the most cost-effective approach. Trial registration chictr.org.cn registration number ChiCTR2200065994. |
| format | Article |
| id | doaj-art-ffc81e3e19bb4d8dbd85177781946966 |
| institution | DOAJ |
| issn | 1471-230X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Gastroenterology |
| spelling | doaj-art-ffc81e3e19bb4d8dbd851777819469662025-08-20T03:05:21ZengBMCBMC Gastroenterology1471-230X2025-05-012511810.1186/s12876-025-03981-1Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatmentPeiwen Dong0Lin Lin1Kaidi Sun2Feng Tang3Qian Li4Xinxu Zhou5Fuli Liu6Zhilin Yang7Jiao Li8Lin Jiang9Ping Zhao10Xiaobin Sun11Qiong Wang12The Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityThe Third People’s Hospital of Chengdu, The Affiliated Hospital of Southwest Jiaotong UniversityAbstract Aim The aim of this study was to explore the accuracy of the diagnosis of gastro-esophageal reflux disease (GERD) through tegoprazan treatment trials, and to analyze factors that may influence test accuracy. Methods This was a single-blind, single-arm 2 weeks tegoprazan treatment trials from March 2023 to April 2024. Patients with ‘typical’ reflux or heartburn as their most troublesome symptom who were considered likely to have GERD were recruited.: Patients were submitted to endoscopy and/or esophageal pH monitoring. After the recording patient used tegoprazan for 2 weeks. This was defined as positive for tegoprazan therapy if the scores for symptoms have decreased to 50%, 75% and 100% of the baseline after 1 and 2 weeks. Calculate different sensitivity, specificity and Youden index for each criterion. Results This represents a mid-term report from the study, with 98 and 91 fully evaluable at one and two weeks. The Youden index indicated that a symptom relief of > 75% after one week offers greater diagnostic value with sensitivity and specificity of 77.5% and 51.9%. Multivariate regression analysis indicated that lower BMI, preference for coffee, endoscopic mucosal erosion, ineffective esophageal peristalsis and positive SAP are independent risk factors predicting the efficacy of P-CAB treatment. Conclusions The P-CAB test (tegoprazan) presents a promising tool for the diagnosis of GERD. A one-week treatment with a criterion of 75% reduction in symptom scores from baseline may be the most cost-effective approach. Trial registration chictr.org.cn registration number ChiCTR2200065994.https://doi.org/10.1186/s12876-025-03981-1TegoprazanGastroesophageal reflux diseaseTreatment trial |
| spellingShingle | Peiwen Dong Lin Lin Kaidi Sun Feng Tang Qian Li Xinxu Zhou Fuli Liu Zhilin Yang Jiao Li Lin Jiang Ping Zhao Xiaobin Sun Qiong Wang Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment BMC Gastroenterology Tegoprazan Gastroesophageal reflux disease Treatment trial |
| title | Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment |
| title_full | Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment |
| title_fullStr | Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment |
| title_full_unstemmed | Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment |
| title_short | Accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium-competitive acid blocker treatment |
| title_sort | accuracy of the diagnosis of gastroesophageal reflux disease by a trial of potassium competitive acid blocker treatment |
| topic | Tegoprazan Gastroesophageal reflux disease Treatment trial |
| url | https://doi.org/10.1186/s12876-025-03981-1 |
| work_keys_str_mv | AT peiwendong accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT linlin accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT kaidisun accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT fengtang accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT qianli accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT xinxuzhou accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT fuliliu accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT zhilinyang accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT jiaoli accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT linjiang accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT pingzhao accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT xiaobinsun accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment AT qiongwang accuracyofthediagnosisofgastroesophagealrefluxdiseasebyatrialofpotassiumcompetitiveacidblockertreatment |